Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer

Sponsor
Chongqing University Cancer Hospital
Study ID
NCT04395612
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • niraparib combined with brivanib — DRUG
    Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Brivanib will be administered as a dose of 400mg orally every day.
  • niraparib combined with toripalimab — DRUG
    Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Toripalimab will be administered as a dose of 240mg Intravenously every 21days.

Study Details

A Clinical Proof-of-concept Study Evaluating Efficacy and Safety of ZL-2306 (Niraparib) Combined With Brivanib or Toripalimab in Patients With Metastatic, Recurrent, and Persistent Cervical Cancer

Key Dates

Start date
May 8, 2020
Status verified
Mar 2021
Primary completion
Apr 1, 2022
Completion
Jul 1, 2022

Study Design

Enrollment
38 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment arm1
    niraparib 200mg/day and brivanib 400mg/day
  • Experimental: Treatment arm2
    niraparib 200mg/day and toripalimab 240mg/21 days

Primary Outcome Measure

ORR [ Time Frame: 6 months ]

Central Contacts

Related Studies